Document:

Exhibit 10.4

 

This SERVICE AGREEMENT (this “Agreement”)
is made as of 5th of July, 2022, by and between Raphael Pharmaceutical INC. (the “Company”),, and DR.
IGAL LOURIA HAYON (the “CTO”/so called “IGAL”). 

 

RECITALS

 

WHEREAS, the Company desires to engage IGAL to
be the Chief Technology officer (so called: “CTO”) & DIRECTOR of the company, and IGAL desires to be the CTO & board
Member on the terms set forth herein;

 

NOW, THEREFORE, in consideration of the mutual
covenants, agreements, representations and warranties contained herein, and intending to be legally bound hereby, the parties hereto hereby
agree as follows:

 

1. Appointment of IGAL to be CTO & DIRECTOR; Relationship
of Company and IGAL.

 

Igal shall provide technological operational support
services to the Company, as hereinafter provided. Igal, at all times, shall be independent of the Company. Nothing contained herein shall
be deemed to make or render the Company a partner, co-venturer or other participant in the business or operations of Igal, or in any manner
to render Company liable, as principal, surety, guarantor, and agent or otherwise for any of the debts, obligations or liabilities of
Igal. Similarly, nothing contained herein shall be deemed to make or render Igal a partner, co-venturer or other participant in the business
or operations of the Company, or in any manner to render Igal liable, as principal, surety, guarantor, and agent or otherwise for any
of the debts, obligations or liabilities of Company.

 

2. Services Descriptions.

 

Commencing on the date of this Agreement, Igal
will provide, supply and render such services, advices and operational support services as are necessary to provide service to the Company
and, as more specifically described below, shall:

 

		a.	Serve as the Chief Technology Officer & Director of the
company.

 

		b.	Represent the company in the Stock Exchange & the SEC
in all Technology maters.

 

		c.	Give the company Medical Advice Services & also sit as
a member of its Medical Committee.

 

		d.	Represent the company in any Health Ministry Country around
the world such as the USA FDA & ISRAELI HEALTH MINISTRY.

 

		It	should be noted that Igal services to the company will not
be contradict or in any conflict of interest to his work in Rambam Health Care Campus.

 

     

     

    

 

3. Obligations of the Company.

 

Igal is the head of the scientific bord and will have the right for
final scientific decision,

 

including but not limited to appointing the scientific bord members,
hiring other consulting or CRO services by the company.

 

Prior to the expiration of this Agreement, the
Company shall provide Igal with true and correct information relating to all functions for which Igal has responsibility hereunder, and
shall not take any action to interfere with Igal’s performance of its duties hereunder.

 

4. Location.

 

During the term of this Agreement, the business
of the Company will be serviced by Igal from the company’s office in Haifa, Israel or any other location selected by the company
and is agreed by Igal.

 

5. Compensation.

 

		a.	Base Compensation

 

While Igal is employed by the Company hereunder
and as otherwise provided in this Agreement, the Company shall pay Igal a monthly fee in the amount of $12,000+expenses related to his
science work payable in advance, with the first payment being due and payable on January 1st , 2023, and each succeeding payment
being due and payable on the first day of each succeeding calendar quarter during the term of this Agreement. The parties agreed that
until December 2022 (include) Igal’s Service Fee will remain $9,000 +expenses per month. 

 

		b.	Benefits:

 

*The company will grant Igal 999,000 Warrants
at an execution price of $0.01 per Warrant. Igal will be able to execute his warrants within two years from the signing date of
this agreement.

 

*In addition to the CTO capacity as the Company’s
R&D consultant for medical Cannabis at the Rambam medical Center, the company appoints Igal to be the company’s COVID-19 project
manager. The parties agreed that the Project manager will be paid in addition to the above considerations, 15% of the net Royalties income
that the company will get for its Medical Cannabis CBD Oil indications sold worldwide for the treatment of COVID-19 patients, and 15%
of the net Royalties income that the company will get for its medical cannabis indication molecules based, for treating Rheumatoid Arthritis
(RA)

 

    2

     

    

 

It should be noted that IGAL will be granted
additional 350,000 warrants at $0.01 cost in case the company will apply for any clinical trial of cannabis based treatment, or will begin
any other new cannabis related research. 

 

It should be noted that the compensation
will be changed in the future according to the Board of Directors of the company decisions, in such a way as it can increase the amount
of fee and/or grant Igal other benefits. 

 

*The company will take care to insure the
board of Directors in a suitable Policy, 45 days after it will start to be a traded company. 

 

6. Term of Agreement; Termination of Rights.

 

(a) The term of this Agreement shall commence
on its execution, and expire, unless terminated or extended in writing, on December 31, 2023. Upon termination of this Agreement, all
books and records relating to the operation of the Business shall be immediately returned to the Company. Notwithstanding the foregoing,
the Company or Igal may terminate this Agreement prior to the expiration of its term upon one hundred & twenty (120) days advance
notice and the payment to Igal of a termination fee equal to three years the fee paid or payable to Igal pursuant to Paragraph 5 herein
for the remaining this Agreement.

 

(b) Company may, at its option, upon ten (10)
days’ written notice terminate this Agreement (if such default is not cured within such ten (10) day period or such longer period as required
to effect a cure if a cure is commenced within 10 days and diligently prosecuted): (i) if Igal shall violate any material provision of
this Agreement; (ii) if Igal shall violate or be in material breach of any provision, representation, warranty, covenant or undertaking
herein; or (iii) if Igal (a) makes an assignment for the benefit of creditors, (b) is adjudicated a bankrupt, (c) files or has filed against
it any bankruptcy, reorganization, liquidation or similar petition or any petition seeking the appointment of a receiver, conservator
or other representative, or (d) proposes a composition arrangement with creditors. The date on which this Agreement is terminated pursuant
to Section 6(a) above or this Section 6(b) is hereinafter referred to as the “Expiration Date”.

 

(c) Igal may, at his option, upon ten (10) days’
written notice terminate this Agreement (if such default is not cured within such ten (10) day period or such longer period as required
to effect a cure if a cure is commenced within 10 days and diligently prosecuted): (i) if Company shall violate any material provision
of this Agreement; (ii) if Company shall violate or be in material breach of any provision, representation, warranty, covenant or undertaking
herein; or (iii) if Company (a) makes an assignment for the benefit of creditors, (b) is adjudicated a bankrupt, (c) files or has filed
against it any bankruptcy, reorganization, liquidation or similar petition or any petition seeking the appointment of a receiver, conservator
or other representative, or (d) proposes a composition arrangement with creditors. The date on which this Agreement is terminated pursuant
to Section 6(a or b) above or this Section 6(c) is hereinafter referred to as the “Expiration Date”.

 

    3

     

    

 

7. Indemnification.

 

(a) Company shall indemnify, defend and hold harmless
Igal and its affiliates, their respective shareholders, officers, directors, employees, and agents, against and in respect of any and
all Losses arising out of or due to the operation of the Business by Company, its affiliates, agents, servants and/or employees prior
to the commencement of the term of this Agreement. The obligations set forth in this Section 6(b) shall survive for a period of ten (10)
year following the Expiration Date.

 

8. Additional Provisions.

 

(a) This Agreement sets forth the entire understanding
and agreement among the parties hereto with reference to the subject matter hereof and may not be modified, amended, discharged or terminated
except by a written instrument signed by the parties hereto.

 

(b) This Agreement shall be governed by, and construed
in accordance with, the laws of the State of ISRAEL applicable to agreements made, delivered and to be performed within such State.

 

(c) This Agreement may not be assigned by Company
or Igal.

 

(d) All of the terms and provisions of this Agreement
shall be binding upon, inure to the benefit of, and be enforceable by each of the parties hereto and their respective successors and assigns.

 

(e) If any provision of this Agreement shall be
determined by a court of competent jurisdiction to be invalid or unenforceable, such determination shall not affect the remaining provisions
of this Agreement, all of which shall remain in full force and effect.

 

(f) This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original but all of which shall constitute one and the same instrument.

 

(g) The headings in this Agreement are for reference
purposes only and shall not in any way affect the meaning or interpretation of this Agreement.

 

    4

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Service Agreement as of the date first above written.

 

Signed this 5th day of July,
2022.

 

	/s/ Shlomo Pilo	 	/s/ Igal Louria Hayon
	 	 	 
	COMPANY	 	CHIEF TECHNOLOGY OFFICER 
	 	 	 
	by:	 SHLOMO PILO, CEO	 	by:	 Dr. Igal Louria Hayon 

 

 

5Exhibit 10.5

 

This SERVICE AGREEMENT (this “Agreement”) is made as of July 5th, 2022, by and between Raphael Pharmaceutical
INC. (the “Company”), and ELIYA YEHUDA I.D 025721069, (the “Director”/so called “Yehuda”).

 

RECITALS

 

WHEREAS the Company desires to engage Yehuda to
be a director of the company, and Yehuda desires to be the director on the terms set forth herein.

 

NOW, THEREFORE, in consideration of the mutual
covenants, agreements, representations and warranties contained herein, and intending to be legally bound hereby, the parties hereto hereby
agree as follows:

 

1. Appointment of Director; Relationship of Company and Yehuda:

 

Yehuda shall serve as a director of the Company,
as hereinafter provided. The Director, always, shall be independent of the Company. Nothing contained herein shall be deemed to make or
render the Company a partner, co-venturer or other participant in the business or operations of Yehuda, or in any manner to render Company
liable, as principal, surety, guarantor, and agent or otherwise for any of the debts, obligations, or liabilities of Yehuda. Similarly,
nothing contained herein shall be deemed to make or render Yehuda a partner, co-venturer or other participant in the business or operations
of the Company, or in any manner to render Yehuda liable, as principal, surety, guarantor, and agent or otherwise for any of the debts,
obligations, or liabilities of Company.

 

2. Services Descriptions.

 

Commencing on the date of this Agreement, Yehuda
will serve as a director in its board of directors.

 

3. Obligations of the Company.

 

Prior to the expiration of this Agreement, the
Company shall provide Yehuda with true and correct information relating to all functions for which Yehuda has responsibility hereunder
and shall not take any action to interfere with Yehuda’s performance of its duties hereunder.

 

4. Location.

 

During the term of this Agreement, the business
of the Company will be serviced by Yehuda from the company’s office Haifa, Israel or any other location in other country selected
by company (subject to the CEO decision).

 

5. Compensation.

 

The company will grant Yehuda 202,000 Warrants
for 2 years at an execution price of $1.12 per share.

 

It should be noted that the compensation will
be changed in the future according to the Board of Directors of the company decisions, in such a way as it can propose Yehuda fees and/or
grant Yehuda other benefits which will not be less than the benefits to which he is entitled in the matter of the warrants, the amount
of the warrants, the price of the warrants and the execution date of the warrants. 

 

*The company will take care for an insurance
to its board of Directors in a suitable Policy. That will occur 45 days after the company will start to be a traded in the stock exchange.

 

    

     

    

 

If an insurance event occurs and as insurance
policy is activated, the company will bear the cost of the deductible. 

 

6. Term of Agreement; Termination of Rights.

 

(a) The term of this Agreement shall commence
on its execution, and expire, unless terminated or extended in writing, on December 31, 2022.

 

(b) Company may, at its option, upon ten (10)
days’ written notice terminate this Agreement (if such default is not cured within such ten (10) day period or such longer period as required
to effect a cure if a cure is commenced within 10 days and diligently prosecuted): (i) if Yehuda shall violate any material provision
of this Agreement; (ii) if Yehuda shall violate or be in material breach of any provision, representation, warranty, covenant or undertaking
herein; or (iii) if Yehuda (a) makes an assignment for the benefit of creditors, (b) is adjudicated a bankrupt, (c) files or has filed
against it any bankruptcy, reorganization, liquidation or similar petition or any petition seeking the appointment of a receiver, conservator
or other representative, or (d) proposes a composition arrangement with creditors. The date on which this Agreement is terminated pursuant
to Section 6(a) above or this Section 6(b) is hereinafter referred to as the “Expiration Date”. (Note: The
warrants as mentioned above in section 5 will be granted to Yehuda even though his terms of contract may terminate upon the condition
of section 6). 

 

7. Additional Provisions.

 

(a) This Agreement sets forth the entire understanding
and agreement among the parties hereto with reference to the subject matter hereof and may not be modified, amended, discharged or terminated
except by a written instrument signed by the parties hereto.

 

(b) This Agreement shall be governed by, and construed
in accordance with, the laws of the State of ISRAEL applicable to agreements made, delivered and to be performed within such State.

 

(c) This Agreement may not be assigned by Company
or Yehuda.

 

(d) All of the terms and provisions of this Agreement
shall be binding upon, inure to the benefit of, and be enforceable by each of the parties hereto and their respective successors and assigns.

 

(e) If any provision of this Agreement shall be
determined by a court of competent jurisdiction to be invalid or unenforceable, such determination shall not affect the remaining provisions
of this Agreement, all of which shall remain in full force and effect.

 

(f) This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original but all of which shall constitute one and the same instrument.

 

(g) The headings in this Agreement are for reference
purposes only and shall not in any way affect the meaning or interpretation of this Agreement.

 

    2

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Service Agreement as of the date first above written.

 

Signed this 5th  day of July 2022.

 

	/s/ Shlomo Pilo	 	/s/ Yehuda Eliya
	 	 	 
	COMPANY	 	Director
	 	 	 
	by: SHLOMO PILO, CEO	 	by: Yehuda Eliya

 

 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]